Evidence map›Paper›PMID 20559327›Full record

ReviewNature reviews. Immunology2010

FOXP3+ regulatory T cells in the human immune system.

Shimon Sakaguchi, Makoto Miyara, Cristina M Costantino, David A Hafler

2 registry-linked trialsAbstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Immunology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 1,227 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1,227citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03236558 nawithdrawnnot on this mapstarted 2018, after this paper: background citation

Thymic Generation of Regulatory T Lymphocytes in Type I Diabetes Patients.

TypeinterventionalSponsorUniversity Hospital, ToulouseRan2018 to 2019Enrolled0ConditionsType1 DiabetesArmsBlood collection
NCT07576699 phase1 / phase2not yet recruitingnot on this mapstarted 2026, after this paper: background citation

CK0802 for Treatment of Steroid Refractory Graft vs. Host Disease (GVHD)

TypeinterventionalSponsorCellenkos, Inc.Ran2026 to 2029Enrolled12ConditionsSteroid Refractory Graft Versus Host DiseaseArmsCK0802 (Allogeneic, Cryopreserved, Cord blood-derived T-regulatory cells, cells that are not HLA matched)
3 · Its place in the literature

Who cites it

1,227 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Article
  7. Article
  8. CD47 and FOXP3Cancers · 2026
    Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Taming immune responses to AAV gene therapy by programmed in vivo Treg expansion.Molecular therapy : the journal of the American Society of Gene Therapy · 2026
    Article
  17. Article
  18. Review
  19. CAR-mediated release of IL-10 increases the function of regulatory T cells: Relevance for future clinical application.Molecular therapy : the journal of the American Society of Gene Therapy · 2026
    Article
  20. Article

1,167 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Shimon SakaguchiDepartment of Experimental Pathology, Institute for Frontier Medical Sciences, Kyoto University, Kyoto 606-8507, Japan. shimon@frontier.kyoto-u.ac.jp
Makoto Miyara
Cristina M Costantino
David A Hafler

Funding

Role of Negative Costimulation in Regulation of AutoimmunityP01AI039671 · NIAID · YALE UNIVERSITY · PI David A. Hafler · 1996 to 2026
$51.7M
The function of T Bet in EAEP01NS038037 · NINDS · BRIGHAM AND WOMEN'S HOSPITAL · PI WEINER, HOWARD L · 2000 to 2010
$12.8M
Role of regulatory CD4+CD25+ T cells in diabetesU01DK061926 · NIDDK · BRIGHAM AND WOMEN'S HOSPITAL · PI HAFLER, DAVID A. · 2001 to 2005
$1.8M
T CELLS IN THE CSF OF MULTIPLE SCLEROSIS PATIENTSR01NS024247 · NINDS · BRIGHAM AND WOMEN'S HOSPITAL · PI HAFLER, DAVID A. · 1987 to 2003
$1.2M
NIAID NIH HHS P01AI39671NIDDK NIH HHS U01DK6192601NINDS NIH HHS P01NS38037NINDS NIH HHS R01NS2424710
6 · The paper itself

Abstract

Forkhead box P3 (FOXP3)(+) regulatory T (T(Reg)) cells are potent mediators of dominant self tolerance in the periphery. But confusion as to the identity, stability and suppressive function of human T(Reg) cells has, to date, impeded the general therapeutic use of these cells. Recent studies have suggested that human T(Reg) cells are functionally and phenotypically diverse. Here we discuss recent findings regarding human T(Reg) cells, including the ontogeny and development of T(Reg) cell subsets that have naive or memory phenotypes, the unique mechanisms of suppression mediated by T(Reg) cell subsets and factors that regulate T(Reg) cell lineage commitment. We discuss future studies that are needed for the successful therapeutic use of human T(Reg) cells.

Indexed as

AnimalsCell DifferentiationForkhead Transcription FactorsHumansImmunologic MemoryImmunotherapyLeukocyte Common AntigensMiceModels, ImmunologicalPhenotypeSelf ToleranceT-Lymphocytes, RegulatoryT-Lymphocyte SubsetsForkhead Transcription FactorsFOXP3 protein, humanFoxp3 protein, mouseLeukocyte Common Antigens

Identifiers

PMID20559327

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.